Loading…

Loading grant details…

Completed HORIZON European Commission

LILY: A Breakthrough Technology to Prevent Chemotherapy-Induced Hair Loss

€4.11M EUR

Funder European Commission
Recipient Organization Luminate Medical Limited
Country Ireland
Start Date Oct 01, 2023
End Date Sep 30, 2025
Duration 730 days
Number of Grantees 1
Roles Coordinator
Data Source European Commission
Grant ID 190130710
Grant Description

Chemotherapy-induced alopecia (CIA) is hair loss associated with chemotherapy treatment for cancer.

LILY is a portable, comfortable, and effective CIA prevention device that uses localised microvasculature compression therapy (LMCT) to prevent CIA.

The LILY device uses this unique LMCT technique to reduce perfusion at the scalp and prevent the destructive action of chemotherapy on hair follicles.

By applying a consistent low-level pressure (between 35 and 60 mmHg) to the local micro blood vessels, which could deliver chemotherapy drugs to fast-dividing hair follicles, the vessels are temporarily compressed, inhibiting drug delivery.The device comprises a proprietary pneumatic bladder network design and soft robotics system with the ability to non-invasively induce vasoconstriction in superficial vessels of the scalp to mechanically control tissue perfusion, and an electronic control system for both patient management of the system and real-time feedback into the treatment protocol.

All Grantees

Luminate Medical Limited

Advertisement
Discover thousands of grant opportunities
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant